Biotech firm Scios ( SCIO) received a thumbs-up late Friday for its heart failure drug, Natrecor, from a panel of advisers to the U.S. Food and Drug Administration. Natrecor is given to patients suffering from acute flare-ups of congestive heart failure, a condition afflicting 5 million Americans. About 1 million of these patients require hospitalizations that cost the healthcare system $23 billion annually. Drugs like Natrecor could help patients suffering from life-threatening heart failure, and also reduce the cost of treatment. Right now, Natrecor stands alone because a rival drug from Genentech ( DNA) suffered a big setback in late-stage testing in April. The full FDA still must approve the drug, but the agency usually goes along with the recommendations of its advisory panels. If Natrecor does get the green light, it will be the first drug approved for Scios, reversing an FDA rejection of Natrecor two years ago. Shares in the Sunnyvale, Calif.-based company were halted all day Friday at $24.56 per share because of the advisory panel meeting. Analysts expect peak sales of Natrecor to reach between $200 million and $300 million annually.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
More from Stocks
Stocks Mixed as Wall Street Looks to G-20 Summit for U.S.-China Trade Talks
Stocks are mixed Monday as investors look to the upcoming G-20 summit for a breakthrough in talks between the world's two largest economies.
Palatin Jumps Then Pulls Back After FDA Clears Sexual-Desire Drug for Women
About 6 million women suffer from hypoactive sexual desire disorder, which Palatin's Vyleesi is designed to treat.
Did the Fed 'Blow It' by Not Cutting Rates? Read My Poll Results
Reliance on the Fed will help to keep support under the market but right now it is just deadly dull while we wait for some sort of news event.